Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFL-101 for Smoking Cessation
NCT04571216Phase 2Completed
- Sponsor
- NFL Biosciences
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Botanical drug
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nfl-101 in nicotine dependence (3 arms), sponsored by NFL Biosciences. Primary endpoints: Rate of participants achieving 4-week continuous abstinence and Rate of participants achieving 6-month continuous abstinence. Started Apr 2021; status: completed.
02
Drugs
nfl-101
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04571216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571216.